Scandion Oncology A/S (OSTO:SCOL) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Scandion Oncology A/S's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Scandion Oncology A/S's long-term debt to total assets ratio declined from Mar. 2023 (0.01) to Mar. 2024 (0.00). It may suggest that Scandion Oncology A/S is progressively becoming less dependent on debt to grow their business.

Scandion Oncology A/S LT-Debt-to-Total-Asset Historical Data

The historical data trend for Scandion Oncology A/S's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology A/S LT-Debt-to-Total-Asset Chart

Scandion Oncology A/S Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Scandion Oncology A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	-	-

Scandion Oncology A/S LT-Debt-to-Total-Asset Calculation

Scandion Oncology A/S's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	51.867
	=

Scandion Oncology A/S's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0	/	40.428
	=

Scandion Oncology A/S (OSTO:SCOL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Scandion Oncology A/S LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Scandion Oncology A/S's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Scandion Oncology A/S (OSTO:SCOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

8VY:Germany

Address

Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100

Website

https://www.scandiononcology.com

Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines